Compare Inovio Pharmaceuticals Inc (INO) vs Prudential Financial Inc (PRU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Prudential Financial Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $0.76 (market cap $78.55M), while Prudential Financial Inc trades at $122.1 (market cap $42.20B). The key difference: Prudential Financial Inc is far larger — about 537.2× Inovio Pharmaceuticals Inc's market cap, and Prudential Financial Inc pays a 4.58% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | PRU | |
|---|---|---|
Market Cap | $78.55M | $42.20B |
Sector | Health | Financials |
52-Week High | $2.87 | $123.93 |
52-Week Low | $0.66 | $92.00 |
Enterprise Value | $49.56M | $70.98B |
Dividend Yield | — | 4.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.
The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.
PRU trades at $122.34, up 0.19% today, with a bullish technical signal from moving averages and support near $122. Recent Q2 2026 earnings beat estimates at $4.08 EPS, driven by strong PGIM and international performance. The company maintains a solid net income margin of 6.04% and ROE of 12.46%, with a dividend of $1.40 declared for September 2026. Revenue trends show growth from 2022 lows, reaching $61.0B in 2025.
Outlook is cautiously optimistic with earnings momentum and strategic focus on capital-light operations, but risks include sensitivity to interest rates and China regulatory news. Analysts are mixed with a $113.11 consensus target below current price, suggesting limited upside. Institutional holdings grew, as seen with Assenagon's 379.8% stake increase in Q2 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →
